<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by João Ribas on Medium]]></title>
        <description><![CDATA[Stories by João Ribas on Medium]]></description>
        <link>https://medium.com/@joaoribas?source=rss-ed6a6b2f4164------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*oMI-wKoE4j-PjZLHqL6aBA.jpeg</url>
            <title>Stories by João Ribas on Medium</title>
            <link>https://medium.com/@joaoribas?source=rss-ed6a6b2f4164------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 15:32:38 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@joaoribas/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Best of 2023: books, podcasts, and more]]></title>
            <link>https://joaoribas.medium.com/best-of-2023-books-podcasts-and-more-4f7147873ac4?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/4f7147873ac4</guid>
            <category><![CDATA[venture-creation]]></category>
            <category><![CDATA[venture-builder]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[innovation]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Fri, 19 Jan 2024 07:04:33 GMT</pubDate>
            <atom:updated>2024-01-19T07:04:33.996Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qY8wesC6iy0dyhnB3FlR8A.png" /><figcaption>Re-imagining Novo Holdings’ office building in Hellerup if it was built by Calatrava (MidJourney)</figcaption></figure><p>As we close the chapter on 2023, it’s time to reflect on a year that buzzed with the energy of reconnection and groundbreaking advancements. 2022 set the stage with its post-COVID resurgence of in-person interactions, a boon for those of us who thrive in the company of others. The year also marked significant professional strides, from the launch of YVC Collective, enhancing collaboration in the European life science VC landscape, to exciting ventures like Engimmune Therapeutics. Navigating the nuances of biotech in Switzerland and moving back to the bustling biotech hub of Boston, 2022 was a year of dynamic shifts and learning.</p><p>As we embraced the wonders of AI tools like ChatGPT, little did we know how integral they would become in our daily lives and professional endeavors. Now, as 2023 draws to a close, let’s dive into how these experiences have shaped our journey, the progress made, and the lessons learned in a year that promised much and delivered even more.</p><blockquote>As predicted last year, the introduction above ☝️ was written by ChatGPT.</blockquote><h4>Learnings and thoughts:</h4><ol><li>I’ve seen further maturation of the portfolio companies I am involved with, and it has been immensely rewarding to see the science pan out and the companies advance through additional financing rounds. From a large Series B to finance multiple trials, to advancing towards Series A with a clear story, plan, and team, it’s been a fantastic year for the portfolio!</li><li>I’ve taken my board work and understanding to the next level, having spent two fantastic weeks at IMD in Lausanne reflecting on my role as a board member and learning how to become a better one. If you are early-ish in your VC career and have a few years of experience on the board of several companies, I strongly recommend taking one of these courses!</li><li>The company where I have an operating role has matured even further. It’s been fantastic to help it grow from an empty shell to a team of over 10 members. I feel more attuned to what management teams do and have a deeper understanding of various operational challenges. I ultimately believe this is making me a better early-stage investor. It’s time to start thinking about the next company I will help build and shape!</li><li>I made the decision to divest from one of our portfolio companies. This decision entailed various challenges in stakeholder management. The investment thesis no longer made sense, therefore it was the best decision, but still a difficult one to take and manage. This experience reinforced the inherent risks in early-stage ventures and the critical importance of effective risk management.</li><li>I have become much better at navigating parenthood and balancing it with work. It’s truly incredible how much more productive and focused I’ve become since time is always scarce. Reading books as been completely transformed into listening to books while commuting to work!</li></ol><h4>Books</h4><p>Not a great number of outstanding books in 2023, but the two books below were my favorites.</p><ol><li><em>Between Two Kingdoms</em> by Suleika Jaouad. A moving and powerful memoir of Suleika’s battle against acute myeloid leukemia. A must for anyone working in the healthcare/biotech space. It illuminates the human side of battling cancer and the impact it can have on one’s life.</li><li><em>The Good Life</em> by Robert Waldinger and Marc Schulz. The book reflects on lessons from the Harvard Study of Adult Development, which is the longest scientific study of human happiness. In essence, it boils down to the strength of our relationships. So simple yet so complex!</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/660/1*mYAiNr41WbuXEVY5HNAjjw.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/994/1*jxEJAlRiLiwZB8_gqieZTg.jpeg" /><figcaption>My top books of 2023</figcaption></figure><h4>Podcasts</h4><p>In 2023, my podcast listening totaled around 120 hours of engaging and diverse content. I discovered a booming ecosystem of podcasters in Portugal, so much of my listening has been in Portuguese. Here are some standout episodes that captured my attention and provoked thoughtful reflection.</p><ol><li>Three episodes from The Long Run podcast by Luke Timmerman, namely the interviews with John Maragnore, Zach &amp; Alexis (Curie.Bio), and Deborah Palestrant (4:59am initiative from 5AM Ventures).</li><li>Two episodes by Guy Raz, namely the interviews with Jørgen Vig Knudstorp on Lego and Sal Khan on AI&#39;s transformational impact on learning &amp; education.</li><li>The entire series “O CEO é o limite” in Portuguese by Cátia Mateus (Expresso).</li><li>Insightful interview with Daniel Ek (Spotify) by Ali Abdal, where Daniel talks about how he manages his schedule (among many other things).</li></ol><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fplaylist%2F3q2ilR3qHxVe59cie76twS%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fplaylist%2F3q2ilR3qHxVe59cie76twS&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67706c0000da846566217760d7872b2c3ec285&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="352" frameborder="0" scrolling="no"><a href="https://medium.com/media/412831e6e224ffea7b59fbae53cce9da/href">https://medium.com/media/412831e6e224ffea7b59fbae53cce9da/href</a></iframe><h4>Resources</h4><ol><li><a href="https://www.pillar.vc/playlist/">Founder Playlist</a> by <a href="https://medium.com/u/b385064eaaea">Pillar</a> is a phenomenal collection of templates, articles, and other resources for startups. What a treasure trove!</li></ol><h4>Art endeavors and discoveries</h4><p>2023 was my first attempt at lino printing, and I’ve produced 9 copies of the work below, reflecting on the scientific advances in genome editing. The 0/9 print, along with individual sections of the composite image, are framed and hanging in our Novo Holdings’ Boston office (shown below).</p><p>In 2023, I also discovered more of Refik Anadol’s work and added data sculptures to my list of artistic endeavors to explore. They could be a unique way of exploring the new era of scientific big data. I spent nearly an hour sitting and observing his data sculptures at ARKEN. It was particularly engaging to see how much my 2-year-old son was in awe! A couple of other interesting works I’ve seen in 2023 are below.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*GXTnLAT5_WOMVAX19urvUA.jpeg" /><figcaption>My first lino printing reflects on the new era of genome editing.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*n3GkN469Do0d1gAkFNAH9Q.jpeg" /><figcaption>Data sculpture by Refik Anadol</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IAFQwU67NETCd6iGKrKhgQ.jpeg" /><figcaption><a href="https://www.sfmoma.org/artwork/97.524/">Mark Rothko, №14, 1960</a></figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HwdCGyMJAhZX8WfWYfa5hg.jpeg" /><figcaption>María Berrío, <em>The Crossing</em>, 2023</figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4f7147873ac4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Neuromuscular disease treatments moving in the right direction]]></title>
            <link>https://medium.com/de-novo/neuromuscular-disease-treatments-moving-in-the-right-direction-7a3a668650ea?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/7a3a668650ea</guid>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Wed, 15 Nov 2023 08:09:02 GMT</pubDate>
            <atom:updated>2023-11-15T08:09:02.504Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xSbTfVWcPOx_r9Vu2vLgDg.png" /></figure><p>Skeletal muscles are essential for human movement and account for about 40% of the body mass. They enable various behaviors such as breathing, eating, walking, and speaking by contracting in response to electrical signals. These signals originate in the brain and travel through motor neurons to reach the target muscle. The motor neuron signals are then transmitted to muscle fibers in a process called neuromuscular transmission. Successful neuromuscular transmission is required to activate muscle contractions. However, if neuromuscular transmission is impaired, movement can become difficult.</p><p>Neuromuscular diseases are a group of disorders that affect approximately 14 million people globally and are characterized by progressive damage to muscle fibers. They can result in symptoms such as muscle weakness and excessive fatigue, which can occur at any stage in the activation of muscle fibers. Some neuromuscular diseases have a genetic basis or an autoimmune etiology, while others have no known genetic cause and develop during a person’s lifetime.</p><p><strong>Spinal muscular atrophy</strong> (SMA) is an example of a genetic condition that affects the motor neuron and the neuromuscular junction (where nerves and muscle fibers meet). It is a progressive neurodegenerative disorder that affects the motor nerve cells in the spinal cord and impacts the muscles used for activities such as breathing, eating, crawling, and walking [<a href="https://www.curesma.org/">1</a>].</p><p><strong>Myasthenia gravis</strong> (MG) is a chronic autoimmune neuromuscular disease that manifests clinically as muscle weakness and muscle fatigue. Although some patients only experience ocular symptoms, the majority have more generalized symptoms. An exacerbation of generalized muscle weakness can result in a life-threatening myasthenic crisis, requiring respiratory support. Beyond muscle weakness and muscle fatiguability, many patients also report central fatigue, experienced as a lack of physical and/or mental energy, which is associated with reduced quality of life [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540870/pdf/40120_2021_Article_285.pdf">2</a>].</p><p><strong>Charcot-Marie-Tooth </strong>(CMT) is a group of inherited conditions that damage the peripheral nerves. The peripheral nerves are found outside the main central nervous system and control the muscles. CMT causes muscle weakness, and reduction in muscle size (atrophy), and some loss of sensation in the lower legs and feet. CMT also often causes contractures (stiffened joints due to abnormal tightening of muscles and associated tissues), and sometimes, curvature of the spine (scoliosis or kyphosis). There are no US Food and Drug Administration or European Commission approved therapies for CMT, but physical therapy, braces and other orthopedic devices, and even surgery can help individuals manage and improve symptoms [<a href="https://www.mda.org/disease/charcot-marie-tooth">3</a>]. Additional treatments are needed to help relieve symptoms, aid mobility, and increase independence and quality of life for people with the condition.</p><p>Neuromuscular conditions can have a profound impact on a person’s functional tasks. Those living with these conditions often struggle to live independent lives. Many of these conditions have no cure, but some treatments can help manage the symptoms and slow down the disease progression. Some prescription medications can alleviate muscle pain, cramps, stiffness, and weakness, while others can address nerve impulses and muscle strength. Additionally, if the disorder is caused by autoimmune issues, like MG, immunosuppressant or immunoglobulin therapies can be recommended. Other treatments include physical therapy and assistive devices. However, many neuromuscular diseases still lack effective therapies, with very few options approved that target the muscle, and this area represents one with a significant unmet need.</p><p>Yet, there is hope for patients living with these conditions as new treatment options are being explored.</p><h3><strong>NMD Pharma: An active future made possible by the power of science</strong></h3><p>NMD Pharma is discovering and developing novel therapeutics for neuromuscular diseases by developing new muscle-targeted approaches to improve the activation of the muscle fibers at the neuromuscular junction. The Company is currently developing this approach for three different neuromuscular disorders: spinal muscular atrophy, myasthenia gravis, and Charcot-Marie-Tooth disease.</p><p>NMD Pharma’s unique experimental platform focuses on ion channel function and electrophysiology of skeletal muscles. The Company is developing small molecules that block a specific type of ion channel (ClC-1) that is found only in skeletal muscles. These molecules could have a beneficial effect on various neuromuscular diseases where muscle activation is failing causing muscle weakness and excessive fatigue, which limit patients’ ability to move and live independently.</p><p>In November 2023, NMD Pharma announced it has raised €75 million in Series B financing to further progress the development of its lead programs. Proceeds from the financing will be used to complete three Phase 2 studies with NMD670, the Company’s lead ClC-1 inhibitor. The three studies will evaluate the novel mechanism of ClC-1 inhibition in AChR and MuSK antibody-positive myasthenia gravis (gMG), spinal muscular atrophy (SMA), and Charcot-Marie-Tooth (CMT) disease, respectively.</p><p>We spoke to <strong>NMD Pharma’s CEO and Co-Founder,</strong> <strong>Thomas Holm Pedersen, </strong>and <strong>Partner, Morten Graugaard Døssing of Novo Holdings,</strong> to find out about the Company, its recent financing, and plans for the future.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/1*SvUVr23eteeKy-qyJYzmRQ.jpeg" /><figcaption>Thomas Holm Pedersen, CEO and co-founder of NMD Pharma</figcaption></figure><h4><strong>Thomas Holm Pedersen, CEO and co-founder of NMD Pharma</strong></h4><p><strong>1.</strong> <strong>When you founded NMD Pharma in 2015, what was your vision?</strong></p><p><em>NMD Pharma has of course changed a lot since it was founded in 2015. It is now more established and a clinical-stage company. However, our vision has not fundamentally changed. It remains all about creating a future in which patients with neuromuscular disease live better and more independent lives.</em></p><p><strong>2.</strong> <strong>What advances does NMD Pharma bring to addressing this unmet medical need?</strong></p><p><em>We have a unique experimental platform focusing on ion channel function and the ability to activate the skeletal muscle under conditions of weak or inconsistent signalling from the brain and neuron. With this platform we are developing small molecule inhibitors of skeletal muscle-specific CIC-1 ion channels that aim to enhance muscle force production, muscle quality, and ultimately to provide meaningful improvements in muscle function and mobility. We also plan to further explore the initial preclinical data that suggests the potential of our platform to add new neuronal connections to skeletal muscle or strengthen newly formed connections under dysfunction caused by disease.</em></p><p><strong>3.</strong> <strong>How has NMD670 performed in Phase 1 trials?</strong></p><p><em>In October 2022 we announced top-line results from a Phase I/IIa clinical trial of NMD670 in patients with myasthenia gravis. The data provided the first clinical proof of the mechanism of action of NMD Pharma’s ClC-1 chloride ion channel inhibitor in patients suffering from myasthenia gravis. NMD670 was found to be safe and well tolerated, with clinically significant improvements in the Quantitative Myasthenia Gravis Score in patients and changes in electrophysiological endpoints that demonstrated target engagement and restoration of neuromuscular transmission.</em></p><p><strong>4.</strong> <strong>How will the recent funding be used?</strong></p><p><em>We plan to accelerate the development of our lead drug candidate (NMD670) in already planned Phase 2 clinical studies for generalized MG and SMA and will also allow us to expand into a Phase 2 clinical trial for CMT. With this funding, we now have a higher probability of successfully helping even more patients suffering from rare neuromuscular diseases. Additionally, the funding allows us to advance additional assets in the pipeline from preclinical stages into the clinic, build our team and capabilities in Denmark, and establish a strong and growing presence in the United States.</em></p><p><strong>5.</strong> <strong>What are the upcoming milestones we can expect to see from NMD Pharma in the next 12 months?</strong></p><p><em>We plan to initiate three Phase 2 clinical studies of NMD670 in MG, SMA, and CMT over the next 12 months. We’ll also be able to recruit more employees in the organization in Denmark and the US.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*UTFqh-DvWqPTY_6aHoNb3g.jpeg" /><figcaption>Morten Graugaard Døssing, Partner at Novo Holdings</figcaption></figure><h4><strong>Morten Graugaard Døssing, Partner at Novo Holdings</strong></h4><p><strong>1.</strong> <strong>When you invested in NMD Pharma in 2016, what made the Company stand out?</strong></p><p><em>We were attracted to the deep scientific understanding of the founding team as it related to the pathophysiology of a range of neuromuscular disorders and of the specific role of the ClC-1 ion channel in modulating muscle contractility. The team had really pioneered this field and had a well-thought-through therapeutic rationale for how to improve muscle function in areas of significant unmet medical need.</em></p><p><strong>2.</strong> <strong>What was Novo Holdings’ role in the start of the Company?</strong></p><p><em>Novo Holdings worked with the team while still at the University of Aarhus and provided pre-seed funding to validate the concept in an in-vivo model of myasthenia gravis. As part of the funding, we provided access to professional guidance and know-how, which has been critical for the successful development and transformation of NMD Pharma from a start-up to a fully integrated biotech company.</em></p><p><strong>3.</strong> <strong>What excites you about NMD Pharma?</strong></p><p><em>Almost 90% of neuromuscular diseases are classified as rare diseases and NMD is truly addressing a high unmet medical need with a unique experimental platform focused on the discovery of novel targets for developing first-in-class treatments.</em></p><p><strong>4.</strong> <strong>How do you plan to continue to support the Company following its recent financing round?</strong></p><p><em>As a board representative on behalf of Novo Holdings, I will continue to be a strong supporter of the company. We are highly active investors with a hands-on approach, and I have frequent catch</em><strong>-</strong><em>up calls with various members of the team on different topics — from introductions to other potential investors to pharma companies looking to understand more about NMD and our unique approach.</em></p><p><strong>5.</strong> <strong>How will patients with Neuromuscular disorders benefit from the potential impact of NMD Pharma’s lead therapeutic?</strong></p><p><em>The ultimate goal for NMD Pharma’s pipeline is to improve symptoms, increase mobility, and improve quality and length of life. In addition, we are exploring a potential disease-modifying effect of our treatment due to the prolonged function of the muscle fibers which seems to have a more longer-term effect and durable effect on patients.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7a3a668650ea" width="1" height="1" alt=""><hr><p><a href="https://medium.com/de-novo/neuromuscular-disease-treatments-moving-in-the-right-direction-7a3a668650ea">Neuromuscular disease treatments moving in the right direction</a> was originally published in <a href="https://medium.com/de-novo">de novo</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Atrial Fibrillation on the Rise: Challenges and Opportunities for Safer Treatment Options]]></title>
            <link>https://medium.com/de-novo/atrial-fibrillation-on-the-rise-challenges-and-opportunities-for-safer-treatment-options-a28825d1de16?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/a28825d1de16</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[atrial-fibrillation]]></category>
            <category><![CDATA[heart-disease]]></category>
            <category><![CDATA[cardiology]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Thu, 28 Sep 2023 07:06:01 GMT</pubDate>
            <atom:updated>2023-09-28T07:06:01.588Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/692/1*WtU5n22ogEnibogqIR-dog.png" /></figure><p>Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia, affecting an estimated 4.5 million people in Europe alone.</p><p>AF mostly affects the elderly population, impacting an estimated 5–10% of people over the age of 70. An ageing population is a key contributor to the rise in AF prevalence, which, in the EU and US combined is predicted to affect 25 million patients by 2030.</p><p>AF is associated with an impaired quality of life, an increased rate of hospitalization, and an increased risk of stroke and death. AF-related strokes are currently estimated to account for up to 20% of all strokes. The expected rise in AF patients will also cause a major increase in the economic burden of AF patients.</p><p>AF patients are often treated with antiarrhythmic drugs as well as anticoagulants to prevent stroke, but invasive ablation techniques such as pulmonary vein isolation are also used as a treatment in some patients. Antiarrhythmic pharmacological treatments include:</p><ul><li>“Acute cardioversion” of AF, aimed to bring the heart back to its normal rhythm (sinus rhythm)</li><li>“Maintenance therapy”, a chronic drug therapy aimed at maintaining sinus rhythm and preventing the recurrence of AF.</li></ul><p>These existing drug therapies generally have a limited effect and are associated with the risk of serious adverse events, hence, there is a considerable patient need for developing better and safer drugs.</p><p><strong>Acesion Pharma’s Breakthrough: SK Channel Inhibition Offers New Hope for Atrial Fibrillation Treatment</strong></p><p>A Novo Seeds portfolio company, Acesion Pharma ApS, develops more efficacious and safe drugs for the treatment of AF. Acesion Pharma aims to achieve this through novel drugs that inhibit SK ion channels, which are relevant for regulating heart rhythm.</p><p>In March of 2023, Acesion announced positive Phase 2 data where clinical proof of mechanism for SK channel inhibition was achieved — increasing the prospects of a mechanism that could be the first new drug approach to AF in 20 years. Subsequently to these Phase 2 data, the Company published compelling pre-clinical data for its second-generation oral SK channel inhibitor, developed for chronic oral maintenance treatment to prevent AF recurrence, in May of this year.</p><p>We spoke to <strong>Acesion’s CEO,</strong> <strong>Anders Gaarsdal Holst, MD, PhD, </strong>and <strong>Partner, Jørgen Søberg Petersen of Novo Holdings,</strong> to find out about the Company, its recent data, and the outlook for the future.</p><h4><strong>Anders Gaarsdal Holst, Acesion’s CEO</strong></h4><p><strong>What is Acesion’s vision?</strong></p><p>Acesion Pharma will develop more efficacious and safe drugs for the treatment of Atrial Fibrillation (AF), the most common type of cardiac arrhythmia.</p><p><strong>What advances does Acesion bring to addressing this unmet medical need?</strong></p><p>Existing drug therapies generally have a limited effect and are associated with risk of serious adverse events. However, Acesion’s science is based on the novel concept of treating Atrial Fibrillation (AF) by inhibiting the SK channels. SK channels are ion channels present in the heart where they are relevant for regulating the heart rhythm. Acesion and others have generated data showing that inhibiting these channels results in antiarrhythmic effect while avoiding the safety issues of the existing therapies, namely a risk of causing life-threatening cardiac rhythm disturbances (proarrhythmia). This is the first new pharmacological approach to treating AF in the last 20 years.</p><p><strong>How does AP31969 differ from current available treatments on the market?</strong></p><p>AP31969 is a molecule that besides being a potent SK inhibitor is also optimised for removing a lot of the barriers that the existing drugs have for their use. We have ensured that it has a low risk of drug-drug interaction as AF patients are often on a lot of other medications. In essence, what we are aiming for with this molecule is to make it safer for patients and easier to prescribe for the physicians and with this, opening up a much more widespread use of drugs to treat AF.</p><p><strong>What does the preclinical data mean for Acesion?</strong></p><p>The preclinical data generated has shown that AP31969 has a low risk of proarrhythmia with robust differentiation compared to existing drugs. This indicates that AP31969 has an improved cardiac safety profile and provides us with confidence in our plans to progress to a phase 1 trial.</p><p><strong>What’s next for Acesion? What are the upcoming milestones we can we expect to see from Acesion in the next 12 months?</strong></p><p>Upon the positive preclinical results, Acesion has completed toxicology studies for AP31969 in preparation for the phase 1 trial we anticipate to begin within this year (2023).</p><p><strong>What is the potential impact of Acesion’s lead therapeutic in Atrial Fibrillation?</strong></p><p>With the numbers suffering from AF forecast to grow dramatically in the coming years, and with the many safety issues associated with currently available drugs, there is a great unmet need for safer AF treatments. Acesion’s 2nd generation molecule shows great potential for this novel class of compounds for the treatment of chronic AF and will hopefully be able to expand the use of pharmacological therapy for AF.</p><h4><strong>Jørgen Søberg Petersen, MD, PhD, MBA, Partner at Novo Holdings</strong></h4><p><strong>What excites you about Acesion Pharma?</strong></p><p>Acesion is developing a new, novel approach to treating AF, a condition<strong> </strong>forecast to affect 25 million people in the US and EU in 2030. These impressive, first-in-class, clinical proof-of-concept data for its second-generation asset significantly de-risks the Company’s SK channel inhibitor program — the first new approach to treating AF in 20 years.</p><p><strong>What does the future look like for patients with AF?</strong></p><p>Currently, drug therapy for AF is cumbersome and associated with the risk of serious side effects. However, if Acesion succeeds with developing AP31969, this will be a gamechanger as it will be easier for physicians to prescribe these drugs to treat their AF patients.</p><p><strong>What made Acesion stand out?</strong></p><p>Acesion’s technology is based on basic research initiated in 2008 at University of Copenhagen and drug discovery and chemistry insights from the Company NeuroSearch. This provided Acesion with a strong scientific foundation along with a fantastic management team, which we saw great potential in.</p><p><strong>What was Novo Holdings’ role in the start of the Company?</strong></p><p>Novo Holdings initially invested in Acesion in December 2011 and remains the largest shareholder. In addition to capital, Novo Holdings has consistently provided access to professional guidance and know-how, which has been critical for the successful development and transformation of Acesion from a start-up to a fully integrated biotech company.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a28825d1de16" width="1" height="1" alt=""><hr><p><a href="https://medium.com/de-novo/atrial-fibrillation-on-the-rise-challenges-and-opportunities-for-safer-treatment-options-a28825d1de16">Atrial Fibrillation on the Rise: Challenges and Opportunities for Safer Treatment Options</a> was originally published in <a href="https://medium.com/de-novo">de novo</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Hemab’s Blood Clotting Therapies at the heart of human resilience]]></title>
            <link>https://medium.com/de-novo/hemabs-blood-clotting-therapies-at-the-heart-of-human-resilience-1996825f580a?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/1996825f580a</guid>
            <category><![CDATA[bleeding-disorder]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Tue, 23 May 2023 12:07:36 GMT</pubDate>
            <atom:updated>2023-05-23T12:07:36.227Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/827/1*-B3Qvo6dI68o8oRJeN-5NA.png" /></figure><p>While patients with common bleeding and thrombotic disorders have had access to preventative treatments for more than a half-century, no such measures exist for less-common disorders. For these underserved men, women, and children, life is paralyzingly unpredictable. A bleeding or thrombotic event can strike at any moment, from a simple menstrual period to a routine dental procedure, and cause symptoms so severe that by the time they reach a hospital, it may be too late.</p><p>Hemab, a rare bleeding disorder company initially funded through Novo Holdings’ company creation and building efforts, is leapfrogging technological advancements to deliver the first ever prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders to prevent life-threatening complications and offer patients a new lifeline. Hemab’s mission is to ensure that every clotting disorder patient has the security and peace of mind they deserve. Its novel therapies are designed to accumulate, modulate, and at times recruit endogenous clotting factors already present in the blood to the site of injury to enable patients to form clots at the right times and in the right places.</p><p>In February 2023, Hemab announced the closing of its oversubscribed $135M Series B financing to advance the first prophylactic treatments for bleeding and thrombotic disorders. This followed the Company’s $55M Series A financing in July 2021, co-led by Novo Holdings.</p><p>We spoke to <strong>Hemab’s CEO,</strong> <strong>Benny Sorensen</strong> and <strong>Board Director Jørgen Søberg Petersen of Novo Holdings</strong> to find out about the Company, its recent financing, and its outlook for the future.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*dhXpmkK27g2VfWhCG3uSYQ.jpeg" /><figcaption>Benny Sorensen, CEO &amp; President of Hemab</figcaption></figure><h4><strong>Benny Sorensen, MD, PhD, CEO &amp; President of Hemab</strong></h4><p><strong>1.</strong> <strong>What is Hemab’s vision?</strong></p><p><em>Hemab’s vision is to deliver the first ever prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders to prevent life-threatening complications and offer patients a new lifeline.</em></p><p><strong>2.</strong> <strong>What advances does Hemab bring to addressing this unmet medical need?</strong></p><p><em>Leveraging validated advanced technologies and key insights into the biology of clotting,. Hemab’s therapeutic candidates bind the body’s native clotting factor(s) with high specificity and affinity. This binding can stabilize the native clotting factor(s), preventing breakdown and allowing accumulation to therapeutic levels. The state-of-the-art technology also allows, when necessary, to recruit native clotting factors directly to the site of injury.</em></p><p><strong>3.</strong> <strong>How will the funds raised in the latest financing be used?</strong></p><p><em>The financing will support Hemab’s scientific and corporate growth plans through 2025, including the completion of the ongoing Phase 1/2 clinical study of lead candidate HMB-001 in Glanzmann Thrombasthenia. The funds will also be used for the initiation of pivotal studies, the start and completion of Phase 1/2 clinical evaluation for HMB-VWF in von Willebrand disease, and future pipeline evolution. Hemab is — targeting the development of 5 clinical assets by 2025.</em></p><p><strong>4.</strong> <strong>What are Hemab’s upcoming milestones? What can we expect from Hemab in the next 12 months?</strong></p><p><em>In the next 12 months, we expect to complete our Phase 1 clinical study of HMB-001.</em></p><p><strong>5.</strong> <strong>What is the potential impact of Hemab’s lead therapeutic in Glanzmann?</strong></p><p><em>Current treatments for Glanzmann Thrombasthenia are designed to treat bleeding, instead of preventing it. However, Hemab is developing the first ever prophylactic treatment. HMB-001 is a bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets with the other arm. It was designed to be a first-in-class prophylactic treatment for Glanzmann Thrombasthenia with potential for other debilitating rare bleeding disorders.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/1*HAwoHqo6EvChHNAApC8yKw.jpeg" /><figcaption>Jørgen Søberg Petersen, Partner at Novo Holdings</figcaption></figure><h4><strong>Jørgen Søberg Petersen, MD, PhD, MBA, Partner at Novo Holdings.</strong></h4><p><strong>1.</strong> <strong>What excites you about Hemab?</strong></p><p><em>Hemab is developing the first ever preventative treatments for rare clotting diseases. The Company’s pipeline is exciting because it allows for widespread expansion into a range of underserved bleeding and thrombotic disorders and is serving patients that have been left behind despite recent innovative therapies.</em></p><p><strong>2.</strong> <strong>What does the future look like for patients with rare blood-clotting diseases?</strong></p><p><em>With companies like Hemab researching and developing innovative preventative treatment methods, we hope patients with rare blood-clotting diseases will soon have effective first line treatment available to them, to be able to have a safer and better quality of life.</em></p><p><strong>3.</strong> <strong>How does Novo Holdings support companies like Hemab?</strong></p><p><em>We provide capital, network and know-how to transform promising life-science discoveries into successful biotech startups. We focus on company creation and building biotech startups in the Nordic region. Our Seed Investments aims to develop strong and competitive companies that we finance all the way to a commercial exit.</em></p><p><strong>4.</strong> <strong>What is Novo Holdings&#39; investment strategy?</strong></p><p><em>Our mission at Novo Holdings is to invest in innovation to benefit people and the planet.</em></p><p><strong>5.</strong> <strong>What motivated you to invest in Hemab and how do you see its potential for impact?</strong></p><p><em>As a founding investor and the Company’s largest shareholder, we are excited to support Hemab in the next phase of its plan to build the ultimate clotting company, with a Nordic foundation and global footprint. Hemab and its assets hold enormous potential to significantly improve the lives of patients living with rare blood-clotting disorders.</em></p><p><strong>6.</strong> <strong>What was Novo Holdings’ role in the start of the Company?</strong></p><p><em>The Company was created in 2020 by the early-stage investment and company creation team of Novo Holdings. The Seed Investment team worked closely with the founders to develop a commercially attractive business plan to maximize the potential of Hemab’s promising technology platform where Novo Holdings co-led the $55M Series A financing.</em></p><p>Learn more about <a href="https://hemab.com/">Hemab </a>and Novo <a href="https://novoholdings.dk/">Holdings</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1996825f580a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/de-novo/hemabs-blood-clotting-therapies-at-the-heart-of-human-resilience-1996825f580a">Hemab’s Blood Clotting Therapies at the heart of human resilience</a> was originally published in <a href="https://medium.com/de-novo">de novo</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[International Day of Women and Girls in Science — interview with Asgard Therapeutics’ CEO and…]]></title>
            <link>https://medium.com/de-novo/international-day-of-women-and-girls-in-science-interview-with-asgard-therapeutics-ceo-and-93b70220abfa?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/93b70220abfa</guid>
            <category><![CDATA[women-in-business]]></category>
            <category><![CDATA[women-in-stem]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Sat, 11 Feb 2023 18:54:24 GMT</pubDate>
            <atom:updated>2023-02-11T18:54:24.301Z</atom:updated>
            <content:encoded><![CDATA[<h3>International Day of Women and Girls in Science — interview with Asgard Therapeutics’ CEO and co-founder</h3><p><em>Celebrating the International Day of Women and Girls in Science with an interview with Cristiana Pires, co-founder and CEO of Asgard Therapeutics, one of our portfolio companies.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*ubCx9StMbuJx_32lWZUVpA.jpeg" /><figcaption>Cristiana Pires, CEO of Asgard Therapeutics</figcaption></figure><h3><strong>What inspired you to pursue a career in science?</strong></h3><p>My tremendous curiosity growing up and the aspiration to do something meaningful inspired me to pursue a career in science. I have long held an interest in understanding human physiology, disease, and the development of new therapies. I trained as a PharmD and then started my scientific career with a Ph.D. in biomedicine, focusing on using cell reprogramming strategies to develop cell therapies for retinal degeneration. As a Postdoc, I was motivated to use basic scientific discoveries and translate them into innovative therapies that could have a real impact on the lives of patients.</p><p>Together, with my co-founders, we developed innovative technology allowing the induction of antigen-presenting cells using a direct reprogramming approach. This opened a pioneering possibility to develop new cancer immunotherapies to reinstate tumor immunogenicity, leading to the incorporation and spin-out of our company Asgard Therapeutics from Lund University in 2018. I have been CEO of Asgard since its inception and I have devoted my work to bringing our vision of cancer immunotherapy based on in-vivo direct reprogramming to reality.</p><h3><strong>What are the biggest barriers you have faced as a woman in science?</strong></h3><p>I am a trained pharmacist and scientist in the life sciences field, one of the few fields in STEM where women are widely present and successful. As I transitioned to the biotech world, I noticed fewer women in leadership roles in start-ups, companies, and on the investor side. However, I have been, and continue to be, fortunate to meet and interact with strong, successful women, in leading positions such as CEOs, VC investors, mentors, and coaches; all of which have set a great example for me and have helped me along the way.</p><h3><strong>What is your advice for young women looking to forge a career in research/STEM?</strong></h3><p>Trust in your abilities, do not question yourself. Surround yourself with inspirational leaders, who become mentors along the way.</p><h3><strong>What do you enjoy most about working in STEM?</strong></h3><p>My motivation comes from being challenged. As a scientist, there are always new questions, experiments, and concepts to develop, which give an unlimited number of challenges. In the biotech world, the challenges are different, and more focused on how to translate new technology into a new therapy that can benefit patients. These challenges with a sense of purpose are what make me continue my work and keep me motivated to work hard!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=93b70220abfa" width="1" height="1" alt=""><hr><p><a href="https://medium.com/de-novo/international-day-of-women-and-girls-in-science-interview-with-asgard-therapeutics-ceo-and-93b70220abfa">International Day of Women and Girls in Science — interview with Asgard Therapeutics’ CEO and…</a> was originally published in <a href="https://medium.com/de-novo">de novo</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Best of 2022: books, podcasts, and more]]></title>
            <link>https://joaoribas.medium.com/best-of-2022-books-podcasts-and-more-caf24c3ff933?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/caf24c3ff933</guid>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Thu, 19 Jan 2023 15:44:27 GMT</pubDate>
            <atom:updated>2023-01-19T15:44:27.821Z</atom:updated>
            <content:encoded><![CDATA[<p>With 2022 behind I can confidently say this was a post-COVID year with many more in-person meetings than before. As someone who enjoys being surrounded by people, 2022 felt much better than previous years. And yes, I got COVID after avoiding it for a long time (fortunately asymptomatic). Following the tradition of previous years, here are my highlights of 2022. Maybe next year a chatGPT-like tool will write this for me ;)</p><h3>Learnings &amp; thoughts</h3><ol><li>Launched <a href="https://yvc-collective.com/">YVC Collective</a> together with a series of other colleagues. YVC is a network of emerging life science VCs in Europe. We’re here to foster collaboration, networking, exchange of thoughts, and career development. We’ve organized many events and will continue to do so throughout Europe. Reach out if you want to learn more or want to join regional chapters.</li><li>ChatGPT. Wow. Still the tip of the iceberg for AI/ML in our daily lives and it’s already making waves everywhere. These kinds of tools will be must-haves in the very near future. I am already dreaming about GPT-like approaches that I can use to talk to scientific literature — “does X target interfere with Z pathway when blocked at Y spot?” (see more on this under <em>Resources </em>👇)</li><li>This year I was involved in one new seed investment from my team, a Swiss company called Engimmune Therapeutics, using a toolbox to generate the next TCR therapies (T-cells or soluble TCRs). This means I continue building on my experience and understanding of the cell therapy space. If you work in a cell therapy biotech with a novel approach or solving some of the critical bottlenecks I would love to hear about it!</li><li>I’ve continued my executive role in a biotech startup company I am helping build, and have now spent some time in Switzerland. I’ve always been impressed by the quality of life there and how everything just works so well. However, after starting a company there I’ve come to learn about some of their old-school habits (e.g. paper signatures, in 2022!). The operational role has given me another level of appreciation for what management teams need to do and it has been a fantastic experience. I am certain it will make me a better investor and board member.</li><li>2022 also brought another change — moving from Copenhagen back to Boston, albeit temporarily. Riding the T reminded me why Boston is the biotech capital of the world. Where else would you see these kinds of subway ads 👇? It’s rare to not see an ad for a research tool or a clinical study.</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*CJGopu3Y94ug86Enu4jhLg.jpeg" /><figcaption>Ad for a research tool on the subway.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ho2gda98UcNgMN3DrI4dHA.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zrZ2p09l0M-y4opa_IlPhg.jpeg" /><figcaption>Two ads for clinical studies on the subway.</figcaption></figure><h3>Books</h3><ol><li><strong>The Art of Possibility </strong>by Rosamund Stone Zander and Benjamin Zander. I recommend you listen to this book instead of reading it. The audio version has multiple orchestral excerpts (Benjamin Zander is the conductor of the Boston Philharmonic). An uplifting dual-perspective on the sense of possibility through anecdotes and experiences.</li><li><strong>Great at Work</strong> by Morten Hansen brings a fresh perspective on what it takes to be great at work. Focus your attention on fewer things and produce high-quality work products instead of trying to do too much and spreading yourself thin.</li><li><strong>Where Futures Converge</strong> by Robert Buderi. This is a book about Kendall Square, often considered one of the most innovative places on earth (at least for biotech).</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/264/1*SYHfO5B5ArVB5UDIhN_4RA.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/263/1*C8c5PoZemavxf-RuQ7E3OA.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FX6S3QN1DJilq8dGAgN2WA.jpeg" /><figcaption>My top 3 books of 2022.</figcaption></figure><h3>Podcasts</h3><p>It’s been a year with fewer total podcast listens, but I still wanted to share a few episodes that I found particularly interesting.</p><ol><li>Guy Raz started “The Great Creators” and interviewed first Stephen Colbert. Interviewed in the same style of “How I built this w/ Guy Raz”. Really interesting to learn so many new things about Colbert (e.g. he explains why his last name is pronounced like it is).</li><li>Business Wars episode series about Taco Bell and Chipotle. From a business perspective, it is super interesting to learn about the story of these two big chains in the US.</li><li>“A Minha Geração” with Diana Duarte. A top-notch podcast for the Portuguese-speaking folks out there mostly interviews with Portuguese people doing amazing work in various fields.</li></ol><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fepisode%2F1n5CtFAvribEuOOK3fwdvh%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fepisode%2F1n5CtFAvribEuOOK3fwdvh&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1f9ef97bf4938fdd970fae09c2&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/0e811477997bc40cba2f30f5c12af2a5/href">https://medium.com/media/0e811477997bc40cba2f30f5c12af2a5/href</a></iframe><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fepisode%2F79RIEDcJuMGJlHUAjhj5m6%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fepisode%2F79RIEDcJuMGJlHUAjhj5m6&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1f3807fac6ed6d743fb4d91966&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/6c418826306d7e9271278bdccc744ff1/href">https://medium.com/media/6c418826306d7e9271278bdccc744ff1/href</a></iframe><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fshow%2F0zf0NSTSqtUF0u5lXDx9Me%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fshow%2F0zf0NSTSqtUF0u5lXDx9Me&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1f6e0a29db1d7f94d7a86b1fd6&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/6907fb60d755bac33ce3ed8f3c10b0b9/href">https://medium.com/media/6907fb60d755bac33ce3ed8f3c10b0b9/href</a></iframe><h3>Resources</h3><p>Here are a few tools and resources I found in 2022 that could be useful to you:</p><ol><li><a href="https://books.google.com/talktobooks/">Talk to Books</a> — a tool built by Google where you can ask questions to books.</li><li><a href="http://elicit.org/">Elicit.org</a> — a GPT-like tool to ask questions to scientific literature. A more detailed guide to come soon.</li><li><a href="https://nucleate.xyz/">Nucleate</a> — a fantastic organization now present in many cities in US/Europe that fosters innovation. If you have an idea and want to be a biotech founder check out their <strong>Nucleate Activator 2023 Application</strong> <a href="https://nucleate.typeform.com/activator2023?typeform-source=nucleate.xyz">here</a>.</li><li>The documentary “<em>From Controversy to Cure — Inside the Cambridge Biotech Boom</em>”. See below 👇</li></ol><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fplayer.vimeo.com%2Fvideo%2F444879438%3Fh%3Df2b7a53209%26app_id%3D122963&amp;dntp=1&amp;display_name=Vimeo&amp;url=https%3A%2F%2Fvimeo.com%2F444879438&amp;image=https%3A%2F%2Fi.vimeocdn.com%2Fvideo%2F935497381-9df099bf7dc5998da3385ea736938127ccf2e45ecb8c4dd955aa5fe011e8150e-d_1280&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=vimeo" width="1920" height="1080" frameborder="0" scrolling="no"><a href="https://medium.com/media/4a059c6b89870e20a9a4bdfe43f79538/href">https://medium.com/media/4a059c6b89870e20a9a4bdfe43f79538/href</a></iframe><h3>Paintings</h3><p>2022 saw no new paintings, but many projects have started. Hopefully, 2023 will be more productive :)</p><p>But of course, and as many of you did, I played around with DALL-E to generate interesting images and graphical elements. As usual in my artistic work, I was inspired by science. See a few selected works below:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*QfhAhAcjpVpW5DjzJK8qQA.jpeg" /><figcaption>Joao Ribas x DALL-E — all scientific contributions to human health in the style of Salvador Dali</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PQoNbOFiNEaZobPWjya_qg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xcpocrE5Qtzc_vVppoNTtg.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*OgB-KDQzwO7Gz7yIXtvpcA.png" /><figcaption>Joao Ribas x DALL-E — a biotech startup in the style of Basquiat</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*2CF8cW6LI_YAjL1pS2_qkg.png" /><figcaption>Joao Ribas x DALL-E — a contemporary sculpture about cancer</figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=caf24c3ff933" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Entrepreneurs in and out of residence — a dual perspective on the role of EiRs in venture creation]]></title>
            <link>https://medium.com/de-novo/entrepreneurs-in-and-out-of-residence-a-dual-perspective-on-the-role-of-eirs-in-venture-creation-5e5473e5dfd6?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/5e5473e5dfd6</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[company-creation]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Thu, 31 Mar 2022 07:02:50 GMT</pubDate>
            <atom:updated>2022-03-31T07:02:50.201Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*rWQkqt-mElC3ZqMOIh9JIw.jpeg" /></figure><h3><strong>Entrepreneurs in and out of residence — a dual perspective on the role of EiRs in venture creation</strong></h3><p>Article by <a href="https://www.linkedin.com/in/joaoribas/">Joao Ribas</a> (Novo Seeds) and <a href="https://www.linkedin.com/in/martin-bonde-248809/">Martin Bonde</a> (former EiR, <a href="https://biorigin.dk/">BiOrigin</a>).</p><p>Venture capital funds that focus on the venture creation model often build teams of entrepreneurs-in-residence (EiRs). These teams bring a wealth of knowledge and experience in managing biotech companies, which may otherwise be hard to recruit to early-stage company creation projects. By having a dedicated EiR team, venture capital (VC) funds leverage experienced management and/or pharma experts to boost the chances of success of early-stage company creation. We describe below the perspectives of both entrepreneurs and VCs on working together in venture creation.</p><h4><em>The EiR perspective — time and space to create a new venture</em></h4><p>EiRs generally join venture funds with two distinct approaches. Some are looking to find the next company to build and helm, while others join with specific ideas on what to build next. In both cases, partnering with a venture fund early on can expedite the venture creation process and leverage resources harder to find solo.</p><p>From a personal perspective, an EiR takes advantage of having no downtime between positions while continuing active employment until a venture creation project is founded and launched. Within the work EiRs do, there is also often flexibility to transition from one project to another if unsuccessful.</p><p>The support and backing of VCs also mean EiRs have more resources available. They can remain up to speed with trends and analysis on different investment areas and topics and can additionally tap into the VCs’ network as well as directly work with the investment team. This stands in stark contrast with solo entrepreneurs who, by comparison, have limited resources and bandwidth.</p><p>Working on venture creation projects with a VC can lead to a higher chance of closing a financing round. The early understanding of the investor perspective, as well as the EiRs’ experience, can help shape the strategy and development plans of venture creation projects in a more cohesive and comprehensive manner, potentially resonating better with other VCs. Furthermore, access to the VC’s network can facilitate discussions and syndication for financing rounds.</p><h4><em>The Venture Fund perspective — an opportunity to build experienced teams early-on</em></h4><p>Venture funds, namely the ones focusing on venture creation, often build or hire teams of EiRs (some funds may use the term Venture Partner). The make-up of said teams can be very diverse, including serial management teams from biotech companies (C-level) as well as industry veterans from pharma companies.</p><p>From the perspective of accessing talent, VCs that choose to have an EiR team often avoid lengthy and sometimes difficult processes of searching and hiring candidates for new projects. This early-on access to talent allows VCs to augment the working bandwidth they can take on, while simultaneously tapping into and securing talent as it becomes available. EiRs can also seemingly transition from one project to another in case of project attrition, allowing VCs to work faster and smarter by “recycling” management teams.</p><p>Key experts and management hired as EiRs can help shape venture creation projects early on, potentially giving them a higher chance of success or, at least, a faster process to reach a no-go conclusion. The operational experience of EIRs can also drive venture creation projects faster in the earlier stages, as well as avoid mistakes of more inexperienced teams. Finally, the VCs can also tap into the EiR’s network, making it sometimes easier to find talent or consultants for projects, hire and grow teams, or select the best providers such as contract research organizations and more.</p><p>One of the challenges venture creators face is early access to experienced management, to help build and drive new venture creation. Having a group of seasoned EiRs can help VCs drive venture creation projects forward, leveraging the EiR’s experience to shape projects and take the right decisions early on. Ultimately, the interactions between EiRs and VCs can accelerate venture creation and lead to higher chances of success for the benefit of both parties.</p><p>As a venture creator, Novo Seeds has built a team of entrepreneurs-in-residence — <a href="https://biorigin.dk/">BiOrigin </a>— comprised of repeat C-level executives and industry experts. Our EiRs are an important part of our venture creation initiatives and play a crucial role in building them. <a href="https://munatherapeutics.com/">Muna Therapeutics</a>, a company that recently raised a $73M Series A financing round, is an example of the role and impact EiRs can have on building biotech companies.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5e5473e5dfd6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/de-novo/entrepreneurs-in-and-out-of-residence-a-dual-perspective-on-the-role-of-eirs-in-venture-creation-5e5473e5dfd6">Entrepreneurs in and out of residence — a dual perspective on the role of EiRs in venture creation</a> was originally published in <a href="https://medium.com/de-novo">de novo</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Best of 2021: books, podcasts, and more]]></title>
            <link>https://joaoribas.medium.com/best-of-2021-books-podcasts-and-more-dcc8bea7c590?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/dcc8bea7c590</guid>
            <category><![CDATA[books]]></category>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[podcast-recommendations]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Mon, 10 Jan 2022 22:04:18 GMT</pubDate>
            <atom:updated>2022-01-10T22:04:18.954Z</atom:updated>
            <content:encoded><![CDATA[<p>2021 was supposed to be the year we went “back to normal”, but instead we learned about a new normal. In the midst of the pandemic, I became a father, and it has been both rewarding and challenging. I instinctively learned more about being productive and focused than I did from any book on the topic. Well, boostered and still (!) COVID-free, here are my key learnings of 2021 and the usual recommendations of what I enjoyed last year.</p><h3><strong>Learnings &amp; thoughts</strong></h3><ol><li>I led the groundwork on <strong>3 investments this year</strong> (Tribune Therapeutics, Asgard Therapeutics, and Orbis Medicines), which made me incredibly versed in all matters related to due diligence, negotiation, and the plethora of documentation needed (it can be lengthy!).</li><li>I took on a <strong>new challenge as interim <em>Chief Business Officer</em></strong> in one of our portfolio companies. In essence, I am taking on the hat of CEO/COO/CBO whenever needed. It is giving me a tremendous appreciation for the work and challenges management teams face. I also find it incredibly fun and rewarding, and absolutely love the challenge.</li><li>Getting a position in VC can be challenging, and there aren’t many opportunities to learn the business, especially around venture creation. This summer <strong>I ran the first-ever Fellowship at Novo Holdings — the Venture Creator Fellowship</strong>. I had 2 amazing fellows working with me on scoping out new scientific areas and building hypotheses for new company creation.</li><li>Company boards can be very helpful but can also function sub-optimally. I’ve accumulated enough experience through my board positions to understand what approach works best in each situation/problem/development stage. Even though I realize I have much to learn, I feel confident that I can provide real value to company boards and I have a profound conviction that well-run boards can empower management teams and lead to higher chances of success.</li><li>Starting new companies can take longer than expected, and there are so many hurdles along the way. Finding startup communities near you and finding experienced mentors that can help tremendously.</li></ol><h3><strong>Books</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*pDqxqwXLbbRPyIvwubZuFg.jpeg" /></figure><p><strong>Empire of Pain: The Secret History of the Sackler Dynasty</strong> by Patrick Radden Keefe. A riveting book profiling the Sackler family and controversy behind OxyContin.</p><h3>Podcasts</h3><p>I’ll make this short and sweet — two episodes from one of my favorite interviewers (Guy Raz), and one podcast to follow.</p><h4>Guy Raz interviews Noubar Afeyan from Flagship Pioneering</h4><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fepisode%2F4Yp5uwQsRkaS5UyoDYWCmg%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fepisode%2F4Yp5uwQsRkaS5UyoDYWCmg&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1f9b9edffff60a32564e079f85&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/f375783c742a276dece2a07f7a35b98e/href">https://medium.com/media/f375783c742a276dece2a07f7a35b98e/href</a></iframe><h4>Guy Raz interviews former Lego CEO, Jorgen Knudstrop</h4><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fepisode%2F6bttpGXZdx49ggQ5r8MCoM%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fepisode%2F6bttpGXZdx49ggQ5r8MCoM&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1f2fa05c6153b39e99b33dbfe8&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/e0c7ecc6168e910c5dddb0e30a337d52/href">https://medium.com/media/e0c7ecc6168e910c5dddb0e30a337d52/href</a></iframe><p>One podcast to follow is <a href="https://medium.com/u/183f327fce8c">BIOS</a>, done by the folks at <a href="https://medium.com/u/113c820e6a43">Alix Ventures</a>. Relevant and up-to-date interviews with industry leaders.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fopen.spotify.com%2Fembed%2Fshow%2F2HmcPq9k8fYpn60F3hw6Ra%3Futm_source%3Doembed&amp;display_name=Spotify&amp;url=https%3A%2F%2Fopen.spotify.com%2Fshow%2F2HmcPq9k8fYpn60F3hw6Ra&amp;image=https%3A%2F%2Fi.scdn.co%2Fimage%2Fab67656300005f1fa12a053f7938cd81969e777b&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=spotify" width="456" height="152" frameborder="0" scrolling="no"><a href="https://medium.com/media/12a5b965c290b9e42d893cb3c87c749d/href">https://medium.com/media/12a5b965c290b9e42d893cb3c87c749d/href</a></iframe><h3>Resources</h3><p>RA Capital put together an incredibly helpful document for biotechs with tips and insights on how to run effective board meetings. Check it out <a href="https://racap.docsend.com/view/qymjn59guq6au3vm">here</a>. It’s full of insights and recommendations, for biotech management teams and VCs alike. <a href="https://medium.com/u/34c03ece183a">Peter Kolchinsky</a> — your team did an amazing job, thank you!</p><h3>Painting</h3><p>A less productive year in abstract expressionism, but much progress in portraiture.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ui09aZgWQTLNUpMGpwNf1Q.jpeg" /><figcaption>“People, ideas, and groups”, acrylic on canvas, commissioned work (2021)</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*eonazZzfjTzbCkcNLuTtCg.jpeg" /><figcaption>“Isabel Ribas”, oil on canvas (2021)</figcaption></figure><p>Stay healthy and let’s connect this year!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=dcc8bea7c590" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Best of 2020: books, podcasts, and more]]></title>
            <link>https://joaoribas.medium.com/best-of-2020-books-podcasts-and-more-5d903243caa7?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/5d903243caa7</guid>
            <category><![CDATA[books]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[vc]]></category>
            <category><![CDATA[biotech]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Tue, 05 Jan 2021 20:48:19 GMT</pubDate>
            <atom:updated>2021-01-05T20:51:13.277Z</atom:updated>
            <content:encoded><![CDATA[<h3>Best of 2020: learnings, books, podcasts, and more</h3><p>2020 started like any other year but quickly morphed into something new and unexpected. Working from home became a reality, and I was forced to buy an actual desk. Little to no commuting and no business travel was hard — not because I was trying to get miles, but because it is such an integral part of the venture capital business. Here’s what I’ve learned and books/podcasts/etc. that I would recommend.</p><h3>Learnings</h3><ol><li>Building companies under a <a href="https://www.mednous.com/system/files/2020-07/Nordic%20venture%20capital%20RibasD%C3%B8ssing%20JulAug%202020.pdf">venture creation model</a> is hard but incredibly fun</li><li>You can be super-efficient when you work from home, but make sure you book pauses on your calendar to avoid back-to-back Zoom calls</li><li>I miss the serendipity of meeting people in conferences and networking events more than I thought</li><li>Coffee-break Zoom calls can help drive team engagement and spirit</li><li>I often walked around my living room while on calls. This made me realize walking meetings should be more frequent, especially when the weather is nice (Danes will understand!)</li><li>I worked with a Novo Seeds EiR trying to build a newco and learned a tremendous amount about resilience, strategy, and “big-picture” thinking</li><li>I learned about negotiation and what it takes to reach compromise between parties</li><li>Found an amazing Twitter account — <a href="https://twitter.com/VCBrags">VCBrags</a> (VCs congratulating themselves). Check it out for yourselves 😂</li></ol><h3><strong>Books that made me think</strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*do2PtY1t86u4jPhe4hZsYQ.jpeg" /></figure><p><strong>Range: Why Generalists Triumph in a Specialized World </strong>by David Epstein: I felt truly at home reading this captivating book. As someone who jumped from field to field, worked at intersections of fields and has a broad set of interests, I always saw those as potential disadvantages. David makes a case for generalists and against over-specialization, in a world where problems are complex and require you to wear different hats.</p><p><strong>The Uninhabitable Earth </strong>by David Wallace-Wells: A portrait of what would happen to planet earth if we do nothing about climate change. Not a pretty picture, but a great eye-opener to the challenges we face.</p><p><strong>The Great American Drug Deal</strong> by Peter Kolchinsky: The view of RA Capital’s founder on drug pricing in the United States and a proposed model to foster and reward innovation while allowing patients to access affordable generics. It’s a controversial topic that Peter navigates with reason, diligence, and solutions at a time the debate is most alive.</p><h3>Biotech Podcasts you should listen to</h3><p>Luke Timmerman’s <a href="https://timmermanreport.com/the-long-run/">The Long Run</a> takes the prize imho. Consistently good podcasts interviewing biotech leaders, both telling their own story as well as their company’s. Two episodes worth listening to:</p><ol><li><a href="https://www.linkedin.com/in/rosana-kapeller-50231b">Rosana Kapeller</a>’s interview on drugging the repeatome. Rosana was the CSO of Nimbus Therapeutics and is currently the CEO of ROME Therapeutics.</li><li><a href="https://twitter.com/PeterKolchinsky">Peter Kolchinsky</a>’s interview on drug pricing in the U.S. Peter is the Managing Partner of <a href="https://www.racap.com/">RA Capital</a>. If you don’t want to read his book, the podcast is a good alternative.</li></ol><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fw.soundcloud.com%2Fplayer%2F%3Furl%3Dhttps%253A%252F%252Fapi.soundcloud.com%252Ftracks%252F873628486%26show_artwork%3Dtrue&amp;display_name=SoundCloud&amp;url=https%3A%2F%2Fsoundcloud.com%2Flongrunpodcast%2Fep75-rosana-kapeller-on-drugging-the-repeatome&amp;image=https%3A%2F%2Fsoundcloud.com%2Fimages%2Ffb_placeholder.png&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=soundcloud" width="800" height="166" frameborder="0" scrolling="no"><a href="https://medium.com/media/d9f8f2e62f975094c8605689fdb39cad/href">https://medium.com/media/d9f8f2e62f975094c8605689fdb39cad/href</a></iframe><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fw.soundcloud.com%2Fplayer%2F%3Furl%3Dhttps%253A%252F%252Fapi.soundcloud.com%252Ftracks%252F919099627%26show_artwork%3Dtrue&amp;display_name=SoundCloud&amp;url=https%3A%2F%2Fsoundcloud.com%2Flongrunpodcast%2Fep80-peter-kolchinsky-on-pharmas-soul&amp;image=https%3A%2F%2Fsoundcloud.com%2Fimages%2Ffb_placeholder.png&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=soundcloud" width="800" height="166" frameborder="0" scrolling="no"><a href="https://medium.com/media/3787ab13e959a5b2d5975f642d6a2323/href">https://medium.com/media/3787ab13e959a5b2d5975f642d6a2323/href</a></iframe><h3>Articles &amp; misc. I found in 2020</h3><ol><li>The <a href="https://torreya.com/publications/publications.php">reports</a> made by Torreya, e.g. <a href="https://torreya.com/publications/biopharma-market-update-torreya-report-oct29-2020.pdf">Biopharmaceutical sector: update on the financing and deal environment</a></li><li><a href="https://www.bvp.com/atlas/drugs-in-a-virtual-world-the-rise-of-digital-health-solutions-in-clinical-trials">Drugs in a virtual world: The rise of digital health solutions in clinical trials</a> by Bessemer Venture Partners</li><li><a href="https://ncats.nih.gov/translation/maps">Drug Discovery, Development and Deployment Maps</a> made by NCATS(NIH)</li><li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521213/">Decoding DNA data storage for investment</a> by Stanley et al.</li><li><a href="https://moalquraishi.wordpress.com/2020/12/08/alphafold2-casp14-it-feels-like-ones-child-has-left-home/">AlphaFold2 @ CASP14: “It feels like one’s child has left home.”</a> by <a href="https://twitter.com/MoAlQuraishi">Mohammed AlQuraishi</a></li><li><a href="https://www.nature.com/articles/s41587-020-0742-6">A comprehensive library of human transcription factors for cell fate engineering</a> by Alex Ng et al.</li></ol><h3>Painting</h3><p>Working from home had its perks too. With the saved time I was able to paint more and even take oil-painting lessons. A few pieces below.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gpoTJ6bNGl3FgGuw05D-3A.jpeg" /><figcaption>A painting of war — cell therapy at work. Displayed in Novo Seeds’ offices.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7qWOr-QfAy7dfQGXR77odQ.jpeg" /><figcaption>Two commissions I painted this year. The left one is about the coming together of knowledge and people to face humanity&#39;s toughest challenges (located in Boston) and the right one about leading a community of peers through the debate of ideas and initiatives (located in Copenhagen).</figcaption></figure><h3>BONUS: Spotify playlists for work</h3><p>You made it to the end! Here are a few Spotify playlists I listen to while working.</p><ol><li><a href="https://open.spotify.com/playlist/4386YnZvfzYDZL4CbIOG7Y">New Jazz Releases</a></li><li><a href="https://open.spotify.com/playlist/37i9dQZF1DX0SM0LYsmbMT">Jazz Vibes</a></li><li><a href="https://open.spotify.com/playlist/3M0d5cahOvrz97XlesaOZT">Samba Soul &amp; more</a></li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5d903243caa7" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How many stroopwafels does it take to hack a medical problem?]]></title>
            <link>https://joaoribas.medium.com/how-many-stroopwafels-does-it-take-to-hack-a-medical-problem-e4c065fff563?source=rss-ed6a6b2f4164------2</link>
            <guid isPermaLink="false">https://medium.com/p/e4c065fff563</guid>
            <category><![CDATA[design-thinking]]></category>
            <category><![CDATA[utrecht]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[3d-printing]]></category>
            <category><![CDATA[hackathons]]></category>
            <dc:creator><![CDATA[João Ribas]]></dc:creator>
            <pubDate>Sat, 24 Mar 2018 13:12:06 GMT</pubDate>
            <atom:updated>2018-03-24T13:12:06.122Z</atom:updated>
            <content:encoded><![CDATA[<p>This past 17 and 18th of February I was in Utrecht to help organize the <a href="https://www.avicennahackathon.nl/">Avicenna Healthcare Hackathon</a>, fueled by <em>stroopwafels</em>, C<em>hocomel</em>, and a healthy dose of excitement.</p><blockquote>tl;dr -<em> </em>check the video at the end!</blockquote><p>In 2013 I was introduced to healthcare hackathons at Brigham and Women’s Hospital through MIT Hacking Medicine (check out the <a href="https://vimeo.com/75971686">video</a> and see if you can spot me). The problem and solution we presented were, in all fairness, not mind-blowing, but I still loved the experience — perhaps the contagious energy of <a href="https://twitter.com/andreakippolito">Andrea Ippolito</a> helped. Many other hackathon experiences ensued, and I got the chance to be on the other side of the table, organizing hackathons around the world, from <a href="https://www.youtube.com/watch?v=35gYhjMJ5fU">Boston</a> (USA) to <a href="http://sites.ieee.org/ecuador/2015/10/29/ieee-mit-hack-medicina-2015/">Quito</a> (Ecuador) and <a href="http://www.ijidonline.com/article/S1201-9712(17)30250-3/abstract">Vienna</a> (Austria).</p><p>While in Boston, <a href="https://www.linkedin.com/in/amir-h-sadeghi-md-msc-a80aa868/">Hosseen Sadeghi</a>, a good friend and soon-to-be cardiothoracic surgeon, experienced a healthcare hackathon and was inspired to organize one in Utrecht through the <a href="http://avicennaxp.nl/">Avicenna Program</a> he had co-founded. Everything was set in motion and then, it finally happened!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Ifxo0373ljdWL3lAo3s3cQ.jpeg" /><figcaption>The wonderful team behind the Avicenna Hackathon 2018!</figcaption></figure><p>The hackathon venue was state-of-the-art: participants had access to 3D-printing facilities, a fully equipped machine-shop, and technicians to support the projects. A panel of mentors was in and out during the weekend to help provide feedback in specific areas.</p><p>Teams worked on a wide-range of projects — from logistics of medical supplies to 3D-printed pharmaceuticals or automation of pathologist tasks.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*b6a_soaTiNcoYaMdWSDhBg.jpeg" /><figcaption>From left to right, Helen Tsang with her Golden Drop lego prototype, Xenia Shakurova with her 3D printed microscope phone holder for SmartScope, Michael Koek reaching out for a 3D-printed pharmaceutical food, and Dashley Rouwendal with his robotic arm for the elder.</figcaption></figure><p>Several of the teams were able to prototype or code a potential solution (see above). Helen Tsang and her team (Golden Drop) started with several broad ideas until they focused in on a more specific one — monitoring analytes in urine. With some of the legos available they built a toilet to set the stage, then went on to 3D-print the prototype of <em>golden drop</em>, an urine collector and analyzer. Xenia Shakurova worked with other team members (SmartScope) that flew in from the Czech Republic (!) for the hackathon. They had found that pathologists spend a considerable amount of time on laborious tasks that can be automated, such as cell counting on histology slides. The team built an AI-based smartphone app to count and aid the pathologist’s workflow, along with a 3D-printed support that connects a cellphone camera to a conventional optical microscope.</p><p>Michael Koek and his team (Printies), made a case for medication adherence in children. They used a prototype 3D-printer to enable the printing of pharmaceuticals. The focus was on patient experience—they had children and parents engage in a fun drawing activity and then printed the drawing in a candy-like formulation. Dashley Rouwendal told us the story behind his idea — elders often struggle with manipulating and using heavy utensils at home (such as a pan of hot oil in the case of Dashley’s grandmother). His team designed a robotic arm whose movement was controlled by the spatial movement of the elder’s phone, with the ultimate goal of aiding with daily tasks.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*m8wpGqK29cGLZc0iseZsmw.jpeg" /><figcaption>Team SmartScope received the first prize.</figcaption></figure><p>SmartScope won the first prize for its automated analysis and aid tool for pathologists. Several other teams won in-kind prizes that will guarantee further mentoring and development. I can’t wait to see what the teams build in the coming months, either using their current ideas, or on different topics. The takeaway from a hackathon is not just the projects teams build during that weekend but also the tools they learn, which can be useful in any venture they take on in the future.</p><p>All-in-all, the event was a success, and I assure you there were no <em>stroopwafels</em> nor C<em>hocomel</em> left!</p><p>Check out the hackathon video for a peek at what it was like!</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fplayer.vimeo.com%2Fvideo%2F261572470&amp;dntp=1&amp;src_secure=1&amp;url=https%3A%2F%2Fvimeo.com%2F261572470&amp;image=https%3A%2F%2Fi.vimeocdn.com%2Ffilter%2Foverlay%3Fsrc0%3Dhttps%253A%252F%252Fi.vimeocdn.com%252Fvideo%252F690618020_1280x720.jpg%26src1%3Dhttps%253A%252F%252Ff.vimeocdn.com%252Fimages_v6%252Fshare%252Fplay_icon_overlay.png&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=vimeo" width="1280" height="720" frameborder="0" scrolling="no"><a href="https://medium.com/media/76420ca3670f2d3576753d5f48780f84/href">https://medium.com/media/76420ca3670f2d3576753d5f48780f84/href</a></iframe><blockquote>Shout out to <a href="http://www.m-ventures.com/">M Ventures</a> for sponsoring the event and supporting my after-hour endeavors! If you participated in the hackathon <a href="https://twitter.com/RibasJC">let me know</a> about your experience and the progress of your team!</blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e4c065fff563" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>